Loortan (Losartan) is generally applied as a long-term therapy for managing conditions marked by sustained elevated vascular pressure and associated cardiovascular risks, and generally contributes to supportive benefits for vital organs. The medication is commonly used across several core therapeutic domains relevant to chronic systemic stress.

Controlling Chronic High Blood Pressure

This medication is applied in clinical settings where patients generally benefit from continuous assistance for managing essential hypertension (chronic high blood pressure). Loortan plays a role in managing the symptom clusters related to sustained pressure, which often creates noticeable physiological strain on the circulatory system. The therapeutic benefit provides support that helps ease the overall symptom load related to vascular strain, and may assist with maintaining functional stability.

Addressing Specific Cardiovascular Risk and Functional Stress

Loortan is also relevant in clinical settings marked by established end-organ damage, specifically when hypertension has led to LVH. Used across this high-risk domain, it generally contributes to supportive benefits by helping to ease manifestations associated with long-term cardiovascular strain. Furthermore, it is commonly used in patients with high blood pressure and Type 2 Diabetes Mellitus to provide supportive therapeutic benefit by supporting the management of symptoms linked to organ-specific functional stress. This action may assist with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Physiological Strain Loortan is relevant for easing the systemic strain that sustained high blood pressure places on vital organs, contributing to improved comfort during long-term management.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Loortan? — Official Regulatory Information

The eligibility for Loortan (Losartan) is strictly defined by regulatory bodies and classified based on population characteristics and physiological status.

Populations Who Must Not Use Loortan (Contraindicated): Use is absolutely prohibited in patients with known hypersensitivity to losartan or any of its components. It is formally contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury. Furthermore, official labeling prohibits its use in patients with diabetes who are concurrently taking any medication containing aliskiren. Severe hepatic impairment is also cited as an absolute contraindication in various regulatory documents.

Eligibility by Age and Function: Loortan is approved for adults and for children aged 6 years and older for the management of hypertension. Use is not recommended in children under 6 years of age. The medicine is also not recommended in pediatric patients whose estimated Glomerular Filtration Rate (GFR) is less than 30 mL/min/1.73 m^2.

Conditional Use and Restrictions: Use is generally not recommended for women who are breastfeeding. Conditional use is noted in patients with mild-to-moderate hepatic impairment and in those with pre-existing volume or salt depletion.

Interactions with other medicines and products

This section summarizes documented drug-drug and drug-product interactions for Loortan (Losartan) based on official regulatory labeling.

---

Contraindicated and High-Risk Combinations

Category	Interacting Agents	Official Restriction/Risk
Dual RAS Blockade	Aliskiren	Contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m²).
Potassium Risk	Potassium-sparing diuretics (e.g., spironolactone), Potassium supplements, and salt substitutes containing potassium.	Concomitant use is generally not recommended due to the potential for severe hyperkalemia.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration of Losartan with certain other medicines can alter drug levels or result in undesirable additive effects:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): May reduce the blood pressure-lowering effect of Losartan and increase the risk of worsening kidney function, especially in the elderly or volume-depleted patients.
• Lithium: Losartan can decrease the elimination of lithium from the body, leading to an increase in serum lithium levels and potential toxicity. Close monitoring is necessary.
• Agents that alter metabolism: Phenobarbital may decrease Losartan's systemic exposure, while Cimetidine may increase it. Losartan is metabolized by CYP2C9 and CYP3A4 enzymes.

Food: Losartan may be taken with or without food.

Mechanism of Action

Targeting the Angiotensin II Type 1 ( AT1) Receptor

Loortan functions as a selective Angiotensin II Receptor Blocker (ARB), primarily engaging the AT1 receptor found on vascular smooth muscle cells, the adrenal glands, and the heart. The drug and its active metabolite (EXP3174) competitively antagonize this receptor, inhibiting the binding and signaling initiated by Angiotensin II. This antagonism prevents the activation of G-proteins and associated intracellular cascades.

Downstream Physiological Modulation

Inhibition of the AT1 receptor results in the relaxation and increased diameter of arteries (vasodilation), which manifests as a decrease in Total Peripheral Resistance within the circulatory system. Furthermore, the blockade interrupts the signaling to the adrenal glands, limiting the release of Aldosterone. This causes the kidneys to excrete more sodium and water, leading to a decrease in circulating fluid volume (Preload).

Inhibition of Uric Acid Reabsorption

Loortan possesses a secondary mechanism involving the URAT1 transporter in the renal tubules. The drug inhibits this transporter, thereby engaging a separate solute transport system that results in increased renal excretion (uricosuria) of uric acid.

The administration of Loortan (Losartan Potassium) is characterized by a standardized, once-daily oral use protocol. The medication is primarily supplied as film-coated tablets in strengths of 25 mg, 50 mg, and 100 mg. The use of an extemporaneously prepared liquid oral suspension is also included in established protocols.

---

Dosing and Administration

Feature	Instruction
Administration Route	Oral route (swallowed whole).
Standard Adult Dose	Starting dose is 50 mg once daily, adjustable up to a maximum daily dose of 100 mg.
Frequency	Once daily for adult and pediatric regimens.
Timing with Food	May be taken with or without food.

---

Population and Procedural Adjustments

Specific procedural rules define when a dose modification is required. A lower initial dose of 25 mg once daily is utilized for patients who present with mild-to-moderate hepatic impairment or for those with intravascular volume depletion.

The pediatric regimen (ages 6–16 for hypertension) starts at 0.7 mg/kg once daily, not to exceed 50 mg. In the case of an omitted dose, the procedural rule is to skip the missed dose and continue the regular schedule; no compensation is permitted by taking two doses at once. These instructions define the standardized approach for using the medication.

Research Evidence / Overview of Studies for Loortan

Evidence for Use in Essential Hypertension

The foundational research for Loortan (Losartan) primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews. These studies was studied for sustained high blood pressure, typically involving adult participants diagnosed with essential hypertension. The main outcomes measured were numerical changes in Systolic and Diastolic Blood Pressure (SBP/DBP). Findings described patterns related to changes in blood pressure metrics within the studied populations. The research primarily documents data show patterns related to the metrics used to measure blood pressure, which is a common characteristic observed across many drug classes studied for this condition.

Evidence for Use in High-Risk Cardiovascular Scenarios

Research examined the use of Losartan in patients with high blood pressure and conditions associated with cardiovascular events, such as Left Ventricular Hypertrophy (LVH). This research was conducted using large-scale, long-term RCTs that monitored participants over several years. These studies tracked a composite endpoint of major events, including the frequency of cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction. Findings described observed patterns in the rate of stroke occurrence between the Losartan group and the group receiving another blood pressure medicine (Atenolol). What remains uncertain is the applicability of these findings to all groups, as findings indicate that patterns related to event rates were observed differently across certain ethnic subgroups.

Evidence for Use in Kidney Functional Stress (Type 2 Diabetes)

Research has been conducted in patients with Type 2 Diabetes Mellitus who also have signs of kidney involvement (diabetic nephropathy). Studies monitored kidney metrics, including the time to doubling of serum creatinine, the incidence of End-Stage Renal Disease (ESRD), and changes in the level of protein in the urine. Trials reported data showing different patterns related to the time taken to reach these severe endpoints compared to a placebo group. However, existing research provides limited data on whether Losartan may be associated with preventing the initial onset of kidney involvement in diabetic patients who do not yet show signs of protein in the urine.

Common questions about Loortan (FAQ)

---

Q: Does this medication make you sleepy or drowsy?

Official regulatory documents and product labels for Loortan state that drowsiness and sleepiness are listed as common side effects. Because of this, caution may be necessary when performing activities requiring full mental alertness, such as driving or operating machinery. This information is based on data collected during clinical trials.

---

Q: Can I take this medication with alcohol?

Regulatory sources generally indicate that the concomitant use of alcohol is not recommended with this type of psychotropic medication. While clinical studies have not shown that Loortan increases the effects of alcohol, combining alcohol with medicines that affect the central nervous system is often advised against as a general precaution. This information is included as a precaution in the official product warnings.

---

Q: Is this medication safe for children 2 years old?

According to the official product information, the safety and effectiveness of Loortan have not been established in pediatric patients. Therefore, the medication is not approved for use in children in this age group. Regulatory information confirms that this medicine is only approved for use in the populations studied.

---

Q: Is it safe long-term?

The clinical trials used to establish the efficacy (how well it works) of Loortan for depression included studies up to 6 months in duration. As documented in regulatory summaries, the long-term safety of the medication has not been fully evaluated beyond the duration of these initial trials.

---

Q: Can I take this medication with or without food?

The official instructions in the Dosage and Administration section of the label state that Loortan can be taken once daily, either with or without food. This means the presence of food does not significantly affect how the medication is absorbed or works according to the product information.

How to Store and Dispose of Loortan (Losartan Potassium)

Storage Conditions

Loortan tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The medication should be kept in its original container with the lid tightly closed and stored out of the sight and reach of children.

Dosage Form	Required Storage Environment
Tablets	Controlled Room Temperature (20°C–25°C)
Compounded Liquid Suspension	Refrigeration (2°C–8°C) for up to four weeks

Disposal Requirements

Unused or expired Loortan must be disposed of according to local regulations for pharmaceutical waste. The product should not be flushed down a toilet or poured down a drain, and release into the environment must be avoided.